These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35736816)

  • 1. Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation.
    Kumar T; Hobbs E; Yang F; Chang JT; Contreras A; Cuentas ERP; Garber H; Lee S; Lu Y; Scoggins ME; Adrada BE; Whitman GJ; Arun BK; Mittendorf EA; Litton JK
    Clin Cancer Res; 2022 Sep; 28(17):3669-3676. PubMed ID: 35736816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    Blum JL; Laird AD; Litton JK; Rugo HS; Ettl J; Hurvitz SA; Martin M; Roché HH; Lee KH; Goodwin A; Chen Y; Lanzalone S; Chelliserry J; Czibere A; Hopkins JF; Albacker LA; Mina LA
    Clin Cancer Res; 2022 Apr; 28(7):1383-1390. PubMed ID: 35091441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Immune Reaction and PD-L1 Expression Using Multiplex Immunohistochemistry in HER2-Positive Breast Cancer: The Association With Response to Anti-HER2 Neoadjuvant Therapy.
    Hou Y; Nitta H; Wei L; Banks PM; Parwani AV; Li Z
    Clin Breast Cancer; 2018 Apr; 18(2):e237-e244. PubMed ID: 29198959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
    Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
    Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
    Litton JK; Beck JT; Jones JM; Andersen J; Blum JL; Mina LA; Brig R; Danso M; Yuan Y; Abbattista A; Noonan K; Niyazov A; Chakrabarti J; Czibere A; Symmans WF; Telli ML
    Oncologist; 2023 Oct; 28(10):845-855. PubMed ID: 37318349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the PARP inhibitor talazoparib for the treatment of advanced
    Hobbs EA; Litton JK; Yap TA
    Expert Opin Pharmacother; 2021 Oct; 22(14):1825-1837. PubMed ID: 34309473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
    Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
    N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Heterozygosity of
    Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A
    Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer.
    Ahmed FS; Gaule P; McGuire J; Patel K; Blenman K; Pusztai L; Rimm DL
    Clin Cancer Res; 2020 Oct; 26(20):5456-5461. PubMed ID: 32709714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
    Yam C; Yen EY; Chang JT; Bassett RL; Alatrash G; Garber H; Huo L; Yang F; Philips AV; Ding QQ; Lim B; Ueno NT; Kannan K; Sun X; Sun B; Parra Cuentas ER; Symmans WF; White JB; Ravenberg E; Seth S; Guerriero JL; Rauch GM; Damodaran S; Litton JK; Wargo JA; Hortobagyi GN; Futreal A; Wistuba II; Sun R; Moulder SL; Mittendorf EA
    Clin Cancer Res; 2021 Oct; 27(19):5365-5375. PubMed ID: 34253579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Talazoparib to treat BRCA-positive breast cancer.
    Guney Eskiler G
    Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy in Hormone Receptor/HER2+ Early Stage Breast Cancer.
    Vanguri RS; Fenn KM; Kearney MR; Wang Q; Guo H; Marks DK; Chin C; Alcus CF; Thompson JB; Leu CS; Hibshoosh H; Kalinsky KM; Mathews JC; Nadeem S; Hollmann TJ; Connolly EP
    Clin Breast Cancer; 2022 Aug; 22(6):538-546. PubMed ID: 35610143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.